We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.
- Authors
Harrison, Michelle L; Obermueller, Eva; Maisey, Nick R; Hoare, Susan; Edmonds, Kim; Li, Ningfeng F; Chao, David; Hall, Kate; Lee, Chooi; Timotheadou, Eleni; Charles, Kellie; Ahern, Roger; King, D Mike; Eisen, Tim; Corringham, Robert; DeWitte, Mark; Balkwill, Frances; Gore, Martin
- Abstract
Tumor necrosis factor alpha (TNF-alpha) may play a role in renal cell carcinoma (RCC). We performed two sequential phase II studies of infliximab, an anti-TNF-alpha monoclonal antibody, in patients with immunotherapy-resistant or refractory RCC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 29, p4542
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.11.2136